279 related articles for article (PubMed ID: 32703310)
41. The effect of entry and retention in opioid agonist treatment on contact with the criminal justice system among opioid-dependent people: a retrospective cohort study.
Gisev N; Bharat C; Larney S; Dobbins T; Weatherburn D; Hickman M; Farrell M; Degenhardt L
Lancet Public Health; 2019 Jul; 4(7):e334-e342. PubMed ID: 31201133
[TBL] [Abstract][Full Text] [Related]
42. Improved treatment-retention for patients receiving methadone dosing within the clinic providing physician and other health services (onsite) versus dosing at community (offsite) pharmacies.
Gauthier G; Eibl JK; Marsh DC
Drug Alcohol Depend; 2018 Oct; 191():1-5. PubMed ID: 30064001
[TBL] [Abstract][Full Text] [Related]
43. Three-Year Retention in Buprenorphine Treatment for Opioid Use Disorder Among Privately Insured Adults.
Manhapra A; Agbese E; Leslie DL; Rosenheck RA
Psychiatr Serv; 2018 Jul; 69(7):768-776. PubMed ID: 29656707
[TBL] [Abstract][Full Text] [Related]
44. Psychiatric comorbidities in opioid-dependent patients undergoing a replacement therapy programme in Spain: The PROTEUS study.
Roncero C; Barral C; Rodríguez-Cintas L; Pérez-Pazos J; Martinez-Luna N; Casas M; Torrens M; Grau-López L
Psychiatry Res; 2016 Sep; 243():174-81. PubMed ID: 27416536
[TBL] [Abstract][Full Text] [Related]
45. Efficacy and cost-effectiveness of an adjunctive personalised psychosocial intervention in treatment-resistant maintenance opioid agonist therapy: a pragmatic, open-label, randomised controlled trial.
Marsden J; Stillwell G; James K; Shearer J; Byford S; Hellier J; Kelleher M; Kelly J; Murphy C; Mitcheson L
Lancet Psychiatry; 2019 May; 6(5):391-402. PubMed ID: 30952568
[TBL] [Abstract][Full Text] [Related]
46. Prevalence and treatment of opioid use disorders among primary care patients in six health systems.
Lapham G; Boudreau DM; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Samet JH; Saxon AJ; Campbell CI; Glass JE; Rossom RC; Murphy MT; Binswanger IA; Yarborough BJH; Bradley KA;
Drug Alcohol Depend; 2020 Feb; 207():107732. PubMed ID: 31835068
[TBL] [Abstract][Full Text] [Related]
47. The impact of benzodiazepine use in patients enrolled in opioid agonist therapy in Northern and rural Ontario.
Franklyn AM; Eibl JK; Gauthier G; Pellegrini D; Lightfoot NE; Marsh DC
Harm Reduct J; 2017 Jan; 14(1):6. PubMed ID: 28122579
[TBL] [Abstract][Full Text] [Related]
48. Using administrative data to predict cessation risk and identify novel predictors among new entrants to opioid agonist treatment.
Bharat C; Degenhardt L; Dobbins T; Larney S; Farrell M; Barbieri S
Drug Alcohol Depend; 2021 Nov; 228():109091. PubMed ID: 34592705
[TBL] [Abstract][Full Text] [Related]
49. Mortality, Causes of Death, and Predictors of Death among Patients On and Off Opioid Agonist Treatment: Results from a 19-Year Cohort Study.
Skeie I; Clausen T; Hjemsæter AJ; Landheim AS; Monsbakken B; Thoresen M; Waal H
Eur Addict Res; 2022; 28(5):358-367. PubMed ID: 35998586
[TBL] [Abstract][Full Text] [Related]
50. Characteristics and Receipt of Medication Treatment Among Young Adults Who Experience a Nonfatal Opioid-Related Overdose.
Bagley SM; Larochelle MR; Xuan Z; Wang N; Patel A; Bernson D; Silverstein M; Hadland SE; Land T; Samet JH; Walley AY
Ann Emerg Med; 2020 Jan; 75(1):29-38. PubMed ID: 31591014
[TBL] [Abstract][Full Text] [Related]
51. Association between mothers' postoperative opioid prescriptions and opioid-related events in their children: A population-based cohort study.
Bethell J; Neuman MD; Bateman BT; Ladha KS; Hill A; Li G; Wijeysundera DN; Wunsch H
Health Rep; 2020 Jul; 31(6):12-19. PubMed ID: 32672924
[TBL] [Abstract][Full Text] [Related]
52. Mortality and causes of death among patients with opioid use disorder receiving opioid agonist treatment: a national register study.
Bech AB; Clausen T; Waal H; Šaltytė Benth J; Skeie I
BMC Health Serv Res; 2019 Jul; 19(1):440. PubMed ID: 31266495
[TBL] [Abstract][Full Text] [Related]
53. Association of Treatment With Medications for Opioid Use Disorder With Mortality After Hospitalization for Injection Drug Use-Associated Infective Endocarditis.
Kimmel SD; Walley AY; Li Y; Linas BP; Lodi S; Bernson D; Weiss RD; Samet JH; Larochelle MR
JAMA Netw Open; 2020 Oct; 3(10):e2016228. PubMed ID: 33052402
[TBL] [Abstract][Full Text] [Related]
54. Health Care Use and Costs of Children, Adolescents, and Young Adults With Somatic Symptom and Related Disorders.
Saunders NR; Gandhi S; Chen S; Vigod S; Fung K; De Souza C; Saab H; Kurdyak P
JAMA Netw Open; 2020 Jul; 3(7):e2011295. PubMed ID: 32701161
[TBL] [Abstract][Full Text] [Related]
55. Characterizing safer supply prescribing of immediate release hydromorphone for individuals with opioid use disorder across Ontario, Canada.
Young S; Kolla G; McCormack D; Campbell T; Leece P; Strike C; Srivastava A; Antoniou T; Bayoumi AM; Gomes T
Int J Drug Policy; 2022 Apr; 102():103601. PubMed ID: 35124413
[TBL] [Abstract][Full Text] [Related]
56. Trends in opioid toxicities among people with and without opioid use disorder and the impact of the COVID-19 pandemic in Ontario, Canada: A population-based analysis.
Ledlie S; Tadrous M; Bayoumi AM; McCormack D; Cheng C; Besharah J; Munro C; Gomes T
Int J Drug Policy; 2024 May; 127():104392. PubMed ID: 38522177
[TBL] [Abstract][Full Text] [Related]
57. Characterizing the Use of Telepsychiatry for Patients with Opioid Use Disorder and Cooccurring Mental Health Disorders in Ontario, Canada.
LaBelle B; Franklyn AM; Pkh Nguyen V; Anderson KE; Eibl JK; Marsh DC
Int J Telemed Appl; 2018; 2018():7937610. PubMed ID: 29610570
[TBL] [Abstract][Full Text] [Related]
58. Negative Impact of Amphetamine-Type Stimulant Use on Opioid Agonist Treatment Retention in Ontario, Canada.
Morin KA; Vojtesek F; Acharya S; Marsh DC
Front Psychiatry; 2021; 12():782066. PubMed ID: 34987430
[No Abstract] [Full Text] [Related]
59. Barriers and facilitators to opioid agonist treatment (OAT) engagement among individuals released from federal incarceration into the community in Ontario, Canada.
Russell C; Pang M; Nafeh F; Farrell Macdonald S; Derkzen D; Rehm J; Fischer B
Int J Qual Stud Health Well-being; 2022 Dec; 17(1):2094111. PubMed ID: 35787743
[TBL] [Abstract][Full Text] [Related]
60. Infants Born to Opioid-Dependent Women in Ontario, 2002-2014.
Brogly SB; Turner S; Lajkosz K; Davies G; Newman A; Johnson A; Dow K
J Obstet Gynaecol Can; 2017 Mar; 39(3):157-165. PubMed ID: 28343557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
